Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. (VCYT) reported that Jonathan Wygant, its VP and Chief Accounting Officer, had 1,361 shares of common stock withheld on September 2, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. This withholding is explicitly stated not to be a sale. After this transaction, he directly holds 43,226 shares, which include 514 shares purchased on July 31, 2026 under Veracyte’s Employee Stock Purchase Plan. No transactions are reported under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) reported an insider equity event involving Global Chief Commercial Officer John Leite. On September 2, 2026, Leite had 3,961 shares of common stock withheld at $44.88 per share to satisfy tax withholding obligations tied to vesting restricted stock units.
The filing states this was a tax-withholding disposition and not an open-market sale. After this transaction, Leite directly held 128,344 shares of Veracyte common stock. No transactions were made under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) reported that Chief Scientific & Med Officer Phillip G. Febbo sold common stock in planned transactions and had shares withheld for taxes. On September 4, 2026, he sold 10,405 shares at $42.8933 per share and 2,705 shares at $43.6618 per share in open-market or private transactions pursuant to a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,639 shares at $44.88 per share were withheld to satisfy tax withholding obligations upon vesting of restricted stock units, which the company states does not represent a sale.
VERACYTE, INC. (VCYT) reported that Chief Financial Officer Rebecca Chambers sold common stock and had shares withheld for taxes. On September 4, 2026, she sold 2,477 shares at a weighted-average price of $42.8059 and 1,175 shares at $43.7140 in open-market or private transactions under a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,603 shares were withheld at $44.88 per share to satisfy tax withholding obligations upon vesting of restricted stock units and did not represent a sale.
VERACYTE, INC. (VCYT) reports that Annie McGuire, EVP and General Counsel, disposed of common stock in several transactions. On September 4, 2026, she sold 2,154 shares at a weighted average price of $42.79 and 1,100 shares at a weighted average price of $43.67, in open-market or private transactions made under a Rule 10b5-1 plan adopted on August 29, 2025. On September 2, 2026, 3,215 shares were withheld to satisfy tax obligations upon vesting of restricted stock units, which the company states does not represent a sale.
VERACYTE, INC. (VCYT) reported that Chief Executive Officer and director Marc Stapley had 8,782 shares of common stock withheld on September 2, 2026 to satisfy tax withholding obligations related to vesting restricted stock units; this is reported as a disposition but is explicitly described as not representing a sale.
Following this withholding, he directly holds 432,073 shares of Veracyte common stock, which includes 361 shares purchased on July 31, 2026 under the Veracyte, Inc. Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is indicated for this tax-withholding transaction.
VERACYTE, INC. (VCYT) has a notice of proposed sale under Rule 144 filed on behalf of officer Ann McGuire. The notice covers the potential sale of 3,254 shares of Veracyte common stock through Morgan Stanley Smith Barney LLC, with an approximate sale date of September 4, 2026. The shares to be sold were acquired on September 2, 2026 as Restricted Stock Units from the issuer. The filing also lists Veracyte common shares outstanding as 80,390,731, which is a baseline figure, not the amount being sold.
VERACYTE, INC. (VCYT) is the issuer of common stock for which officer Rebecca Chambers has filed a notice of proposed resale under Rule 144. The notice covers up to 3,652 shares of common stock, associated with restricted stock units held for her account.
The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of approximately $163,134.84 and a proposed sale date of September 4, 2026 on Nasdaq.
Veracyte, Inc. (VCYT) received a Rule 144 notice that Philip Febbo plans to sell up to 13,110 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares were acquired from Veracyte upon vesting of restricted stock units during the period from March 2, 2026 through September 2, 2026.
VERACYTE, INC. (VCYT) director Muna Bhanji reported selling 1,864 shares of common stock on September 1, 2026 at a price of $42.97 per share in an open-market or private transaction. After this sale, Bhanji directly holds 42,718 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 2, 2026.